2m 2m 2m 2m 2m 2m 2m
BIONXS GENE LAB (BGLC)
NASDAQ
$1.61+$0.004 (+0.25%)
Price as of Sep 11, 2026 4:32 PM EDT- $4.7MMarket Cap
- -70.35%1-Year Change
- Specialty ChemicalsIndustry
BIONXS GENE LAB (BGLC)
$1.61+$0.004 (+0.25%)
BGLC | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $1.61 | ||
Change | +$0.13 (+8.78%) | ||
Open | $1.54 | ||
High | $1.61 | ||
Low | $1.54 | ||
Previous Close | $1.48 | ||
Volume | 1,826 | ||
30-Day Average Volume | 9,226 | ||
1-Week Change | 11.03% | ||
1-Month Change | 5.92% | ||
1-Year Change | -70.35% | ||
3-Year Change | -83.57% | ||
5-Year Change | N/A | ||
Fundamentals | |||
Shares Outstanding | 2.9M | ||
Total Assets | $8.7M | ||
Market Cap | $4.7M | ||
Enterprise Value | $3.5M | ||
Period: QTR TTM FY | |||
Revenue | $76,156.00 | ||
Net Income | -$286,451.00 | ||
Free Cash Flow | -$422,741.00 | ||
EBIT | -$286,451.00 | ||
EBITDA | -$258,386.00 | ||
Net Working Capital | $4.1M | ||
EPS | -$0.12 | ||
Enterprise Value/EBITDA | -14 | ||
Enterprise Value/Revenue | 46 | ||
P/B | 1 | ||
P/E | -14 | ||
PEG | -0 | ||
Price/Free Cash Flow | -11 | ||
Price/Operating Cash Flow | -11 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | 1 : 10 | ||
Last Split Date | 04/07/2025 | ||
Earnings & Revenue